Amgen recalls anemia drugs due to glass flakes

The U.S. Food and Drug Administration has approved revised warnings and labeling changes for the anemia drugs Aranesp, Epogen and Procrit.

U.S. drug regulators are contemplating further restrictions on the use of drugs to combat anemia in cancer patients.

(AP) -- A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Aranesp nearly doubled the risk of stroke in people with diabetes and chronic kidney problems who are not yet sick ...

A new study helps dispel mounting confusion over the safety of blockbuster anemia drugs — erythropoiesis-stimulating agents — for people with kidney disease requiring dialysis, as federal regulators prepare to decide ...

Two former employees with the California biotech company Amgen Inc. allege the company persuaded sales people to access patient records to boost sales.

May 28, 2009 - A new study appearing in Congestive Heart Failure has found that the presence of anemia in patients with chronic heart failure is associated with a significantly increased risk of death. The findings also s ...

An investigational new drug significantly improved a common and debilitating circadian rhythm sleep disorder that frequently affects people who are completely blind, a multicenter study finds. The results were presented Monday ...

The Supreme Court ruled Monday that deals between pharmaceutical corporations and their generic drug competitors, which government officials say keep cheaper forms of medicine off the market, can be sometimes be illegal and ...

A South Florida company is voluntarily recalling weight loss supplements called "JaDera" and "Xiyouji Qingzhi."

Researchers at Johns Hopkins report that hospitalized patients do not receive more than one in 10 doses of doctor-ordered blood thinners prescribed to prevent potentially lethal or disabling blood clots, a decision they say ...

Shares of Elan Corp PLC jumped Friday after the Irish drugmaker said it will explore a possible sale of the company while its board continues to fend off a hostile takeover bid from Royalty Pharma.

(Medical Xpress)—Professor Mark Kendall of the University of Queensland, Australia, has announced at this year's TEDGLobal Conference that a skin patch he and colleagues have developed will soon begin field ...